Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting

被引:1
|
作者
Mannelli, Paolo [1 ]
Douaihy, Antoine B. [2 ]
Akerman, Sarah C. [3 ]
Legedza, Anna [3 ]
Fratantonio, James [3 ]
Zavod, Abigail [3 ]
Sullivan, Maria A. [3 ,4 ]
机构
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, 3074,2213 Elba St,Ste 156, Durham, NC 27705 USA
[2] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA
[3] Alkermes Inc, Waltham, MA USA
[4] Columbia Univ, Dept Psychiat, New York, NY USA
来源
AMERICAN JOURNAL ON ADDICTIONS | 2022年 / 31卷 / 02期
关键词
D O I
10.1111/ajad.13264
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background and Objectives Treatment for individuals receiving medication for opioid use disorder (MOUD) should follow an informed patient-centered approach. To better support patient autonomy in the decision-making process, clinicians should be aware of patient preferences and be prepared to educate and assist patients in transitioning from one MOUD to another, when clinically indicated. This posthoc analysis describes the characteristics of clinical trial participants (NCT02696434) with a history of opioid use disorder (OUD) seeking to transition from buprenorphine (BUP) to extended-release naltrexone (XR-NTX). Methods The posthoc analysis included adults with OUD currently receiving BUP (<= 8 mg/day) and seeking transition to XR-NTX (N = 101) in a residential setting. Baseline participant characteristics and OUD treatment history were reviewed. All patients completed a screening questionnaire that asked about their reasons for seeking transition to XR-NTX and for choosing BUP. Results The most common reasons for initiating a transition to XR-NTX were "Seeking to be opioid-free" (63.4%) and "Tired of daily pill taking" (25.7%). Positive predictors of transition included a more extensive BUP treatment history and a history of prescription opioid abuse. Most participants stated they were not aware of XR-NTX as a treatment option when initiating BUP (78.2%). Discussions and Conclusions Patients' reasons for seeking XR-NTX transition, more extensive BUP treatment history, and a history of prescription opioid abuse, may positively predict outcomes. Scientific Significance These findings may assist clinicians in optimizing outcomes of the BUP to XR-NTX transition and supporting patients to make better informed MOUD decisions.
引用
收藏
页码:142 / 147
页数:6
相关论文
共 50 条
  • [1] Extended-release naltrexone for youth with opioid use disorder
    Mitchell, Shannon Gwin
    Monico, Laura B.
    Gryczynski, Jan
    Fishman, Marc J.
    O'Grady, Kevin E.
    Schwartz, Robert P.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 130
  • [2] Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
    Comer, Sandra D.
    Mannelli, Paolo
    Alam, Danesh
    Douaihy, Antoine
    Nangia, Narinder
    Akerman, Sarah C.
    Zavod, Abigail
    Silverman, Bernard L.
    Sullivan, Maria A.
    AMERICAN JOURNAL ON ADDICTIONS, 2020, 29 (04): : 313 - 322
  • [3] Buprenorphine Extended-Release Treatment for Opioid Use Disorder in the Postpartum Period
    Galati, Bridget M.
    Wenzinger, Michael
    Rogers, Cynthia E.
    Cooke, Emily
    Kelly, Jeannie C.
    OBSTETRICS AND GYNECOLOGY, 2023, 142 (05): : 1148 - 1152
  • [4] Outpatient Transition to Extended-release Naltrexone in Patients With Opioid-use Disorder
    Sullivan, Maria
    Mannelli, Paolo
    Yu, Miao
    Nangia, Narinder
    Graham, Christine
    Webster, Irena
    Tompkins, D. Andrew
    Kosten, Thomas
    Akerman, Sarah
    Silverman, Bernard
    AMERICAN JOURNAL ON ADDICTIONS, 2018, 27 (04): : 323 - 323
  • [5] Comparative effectiveness of extended-release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
    Ross, Rachael K.
    Nunes, Edward V.
    Olfson, Mark
    Shulman, Matisyahu
    Krawczyk, Noa
    Stuart, Elizabeth A.
    Rudolph, Kara E.
    ADDICTION, 2024, 119 (11) : 1975 - 1986
  • [6] Body Mass Index as a Predictor of Extended-Release Naltrexone Treatment Retention in Individuals With Opioid Use Disorder
    Li, Xinyi
    Langleben, Daniel
    Lynch, Kevin
    Wang, Gene-Jack
    Wiers, Corinde E.
    Shi, Zhenhao
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 416 - 416
  • [7] Patterns of withdrawal in patients with opioid use disorder (OUD) transitioning from untreated OUD or buprenorphine treatment to extended-release naltrexone
    Mannelli, Paolo
    Douaihy, Antoine B.
    Zavod, Abigail
    Legedza, Anna
    Akerman, Sarah C.
    Sullivan, Maria A.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2021, 47 (06): : 753 - 759
  • [8] Variants of opioid genes and response to treatment of opioid use disorder with buprenorphine-naloxone versus extended-release naltrexone in Caucasians
    Randesi, Matthew
    Rotrosen, John
    Nunes, Edward, V
    Lee, Joshua D.
    Novo, Patricia
    Levran, Orna
    Ott, Jurg
    Pavlicova, Martina
    Scodes, Jennifer
    Kreek, Mary Jeanne
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2020, 46 (06): : 761 - 768
  • [9] Pregnant and Postpartum Individuals' Knowledge, Attitudes, and Perceptions of Extended-release Buprenorphine for Treatment of Opioid Use Disorder
    Lai, Miao
    Bowman, Justin
    Charles, Jasmin
    Smid, Marcela C.
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (03) : 342 - 345
  • [10] Injecting Opioid Use Disorder Treatment in Jails and Prisons: The Potential of Extended-release Buprenorphine in the Carceral Setting
    Berk, Justin
    del Pozo, Brandon
    Rich, Josiah D.
    Lee, Joshua D.
    JOURNAL OF ADDICTION MEDICINE, 2022, 16 (04) : 396 - 398